Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 8 | 2021 | 59 | 2.290 |
Why?
|
| Bone Substitutes | 4 | 2017 | 4 | 1.020 |
Why?
|
| Bone Transplantation | 5 | 2017 | 82 | 1.000 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2022 | 24 | 0.940 |
Why?
|
| Sarcoma | 5 | 2023 | 59 | 0.840 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 11 | 0.660 |
Why?
|
| Young Adult | 8 | 2021 | 863 | 0.540 |
Why?
|
| Adult | 11 | 2022 | 3557 | 0.490 |
Why?
|
| Sarcoma, Ewing | 1 | 2016 | 5 | 0.490 |
Why?
|
| Bone Cysts | 1 | 2016 | 1 | 0.490 |
Why?
|
| Foot | 1 | 2016 | 17 | 0.480 |
Why?
|
| Foreign Bodies | 1 | 2016 | 16 | 0.470 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2016 | 2 | 0.470 |
Why?
|
| Humans | 21 | 2023 | 12240 | 0.470 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 36 | 0.470 |
Why?
|
| Acetabulum | 1 | 2016 | 81 | 0.470 |
Why?
|
| Adolescent | 8 | 2021 | 989 | 0.420 |
Why?
|
| Hip Joint | 1 | 2016 | 136 | 0.420 |
Why?
|
| Arthralgia | 2 | 2011 | 56 | 0.390 |
Why?
|
| Child | 6 | 2021 | 614 | 0.390 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 2 | 0.340 |
Why?
|
| Talus | 1 | 2011 | 8 | 0.340 |
Why?
|
| Edema | 1 | 2011 | 15 | 0.330 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2010 | 6 | 0.330 |
Why?
|
| Female | 9 | 2021 | 6974 | 0.330 |
Why?
|
| Patellar Ligament | 1 | 2010 | 21 | 0.320 |
Why?
|
| Tibia | 1 | 2010 | 100 | 0.310 |
Why?
|
| Prognosis | 5 | 2023 | 363 | 0.300 |
Why?
|
| Middle Aged | 8 | 2021 | 4043 | 0.290 |
Why?
|
| Child, Preschool | 3 | 2021 | 320 | 0.290 |
Why?
|
| Osteosarcoma | 2 | 2021 | 21 | 0.290 |
Why?
|
| Male | 10 | 2021 | 6815 | 0.280 |
Why?
|
| Bone Plates | 1 | 2008 | 19 | 0.270 |
Why?
|
| Retrospective Studies | 8 | 2023 | 1467 | 0.270 |
Why?
|
| Fractures, Bone | 1 | 2008 | 37 | 0.260 |
Why?
|
| Survival Rate | 3 | 2021 | 152 | 0.240 |
Why?
|
| Calcium Sulfate | 1 | 2005 | 2 | 0.230 |
Why?
|
| Tobramycin | 1 | 2005 | 5 | 0.230 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 726 | 0.230 |
Why?
|
| Humerus | 1 | 2005 | 48 | 0.220 |
Why?
|
| Knee Prosthesis | 1 | 2005 | 92 | 0.210 |
Why?
|
| Margins of Excision | 2 | 2022 | 16 | 0.210 |
Why?
|
| Debridement | 2 | 2016 | 31 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 69 | 0.200 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 19 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 207 | 0.200 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 41 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 32 | 0.190 |
Why?
|
| Neutrophils | 1 | 2023 | 58 | 0.190 |
Why?
|
| Aged | 5 | 2021 | 4000 | 0.190 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.180 |
Why?
|
| Infant | 2 | 2021 | 277 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 2152 | 0.180 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 7 | 0.180 |
Why?
|
| Orthopedics | 1 | 2002 | 32 | 0.180 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2005 | 264 | 0.170 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 93 | 0.170 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 5 | 0.170 |
Why?
|
| Myxosarcoma | 1 | 2020 | 2 | 0.160 |
Why?
|
| Orthopedic Procedures | 1 | 2002 | 111 | 0.160 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 6 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 143 | 0.160 |
Why?
|
| Infant, Newborn | 1 | 2021 | 312 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2023 | 1478 | 0.140 |
Why?
|
| Cohort Studies | 1 | 2021 | 827 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 5 | 0.130 |
Why?
|
| Imidazoles | 1 | 2017 | 34 | 0.130 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 163 | 0.130 |
Why?
|
| Bone Diseases | 1 | 2017 | 9 | 0.130 |
Why?
|
| Piperazines | 1 | 2017 | 41 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 35 | 0.130 |
Why?
|
| Ceramics | 1 | 2016 | 3 | 0.120 |
Why?
|
| Injections | 1 | 2016 | 22 | 0.120 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 42 | 0.120 |
Why?
|
| Allografts | 1 | 2016 | 74 | 0.120 |
Why?
|
| Child Development | 1 | 2016 | 52 | 0.120 |
Why?
|
| Synovectomy | 1 | 2016 | 3 | 0.120 |
Why?
|
| Arthroplasty | 1 | 2016 | 54 | 0.110 |
Why?
|
| Lung | 1 | 2015 | 76 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 168 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 281 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 247 | 0.100 |
Why?
|
| Ankle | 1 | 2011 | 14 | 0.080 |
Why?
|
| Biopsy | 1 | 2011 | 97 | 0.080 |
Why?
|
| Ilium | 1 | 2010 | 19 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 171 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 151 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 218 | 0.080 |
Why?
|
| Apoptosis | 2 | 2022 | 105 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2023 | 817 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 464 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 66 | 0.070 |
Why?
|
| Arthroscopy | 1 | 2011 | 267 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 40 | 0.060 |
Why?
|
| Drug Implants | 1 | 2005 | 2 | 0.060 |
Why?
|
| Bone Cements | 1 | 2005 | 37 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2005 | 8 | 0.060 |
Why?
|
| Dogs | 1 | 2005 | 98 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 141 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 179 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2005 | 195 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 258 | 0.050 |
Why?
|
| Age Factors | 1 | 2005 | 350 | 0.050 |
Why?
|
| Cell Division | 2 | 2022 | 35 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2005 | 229 | 0.050 |
Why?
|
| Reoperation | 1 | 2005 | 366 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 23 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 42 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 10 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 12 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 30 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 36 | 0.050 |
Why?
|
| Bone Matrix | 1 | 2002 | 15 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 2 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 8 | 0.040 |
Why?
|
| Bone Regeneration | 1 | 2002 | 61 | 0.040 |
Why?
|
| Cartilage | 1 | 2002 | 41 | 0.040 |
Why?
|
| Animals | 2 | 2005 | 2092 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 74 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 20 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 34 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 23 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 51 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 297 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 161 | 0.040 |
Why?
|
| Time Factors | 1 | 2022 | 695 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 8 | 0.030 |
Why?
|
| Pyrazines | 1 | 2017 | 7 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 20 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2017 | 12 | 0.030 |
Why?
|
| Cisplatin | 1 | 2017 | 25 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 29 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 128 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 42 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 99 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 85 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 11 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 22 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 59 | 0.020 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 4 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 4 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 4 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 5 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 7 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 12 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 12 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 12 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 54 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 26 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 32 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 275 | 0.010 |
Why?
|